Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
Aberdeen Group plc and its U.S. affiliate abrdn Inc. have filed a Schedule 13G disclosing a passive ownership stake in Sera Prognostics (SERA).
- Shares owned: 2,227,367 Class A common shares.
- Ownership percentage: 6.07% of the outstanding class as of 30 Jun 2025.
- Voting & dispositive power: 0 shares held with sole power; all 2,227,367 shares held with shared voting and dispositive power by both reporting entities.
- Reporting parties: Aberdeen Group plc (UK parent, classified as a Holding Company – “HC”) and abrdn Inc. (US subsidiary, classified as Corporation & Investment Adviser – “CO, IA”).
- Intent: Certification states the position is held in the ordinary course of business and is not intended to influence or control the issuer.
- Structure: Aberdeen Group plc → abrdn Holdings Ltd. → abrdn Inc.; the U.S. adviser holds the shares for underlying clients.
The filing indicates that a sizable institutional investor has surpassed the 5 % threshold, triggering disclosure under Rule 13d-1(b). No changes to company control or strategic direction are signaled.
Sera Prognostics Chief Commercial Officer Dyaarl Lee Anderson Jr. received significant equity compensation on June 23, 2025, consisting of two components:
- 67,114 Restricted Stock Units (RSUs) with a four-year vesting schedule: - 25% vests on June 10, 2026 - Remaining 75% vests quarterly over three years
- 102,534 Stock Options with strike price of $1.87: - 25% vests on June 10, 2026 - Remaining 75% vests monthly over three years
Both grants require continued service with the company. The equity awards suggest a long-term retention strategy for the Chief Commercial Officer position, with zero-cost RSUs balanced against performance-based stock options. The relatively low strike price of $1.87 indicates potential upside opportunity in the company's growth prospects.